FBT Among Technology ETFs
End-of-day Nov 19, 2026 · 39 Technology ETFs by 5Y
| Returns | Today | 1W | 1M | 3M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| Total return | −1.5% | −3.1% | −3.5% | −3.0% | +27.2% | +30.8% | +90.2% | +65.4% | +169.4% | +1,007.4% |
| Peer average | −2.0% | −7.0% | −12.3% | −14.4% | 0.0% | +3.7% | +57.2% | +20.1% | +352.7% | — |
| S&P 500 · VOO | −2.0% | −5.5% | −7.4% | −6.3% | +5.8% | +9.7% | +65.8% | +65.5% | +290.0% | — |
$46 of every $1,000 in FBT is Genmab
| # | ||||||
|---|---|---|---|---|---|---|
| 1 | GMABGenmab A/S () | Healthcare | 4.57% | $456.56 | 2.7M | $135.8M |
| 2 | ADMAADMA Biologics | Healthcare | 4.35% | $434.61 | 9.5M | $129.3M |
| 3 | REGNRegeneron Pharmaceuticals | Healthcare | 4.21% | $420.55 | 132K | $125.1M |
| 4 | TGTXTG Therapeutics | Healthcare | 3.97% | $396.52 | 1.8M | $118.0M |
| 5 | ALKSAlkermes | Healthcare | 3.83% | $383.07 | 2.4M | $114.0M |
| 6 | NBIXNeurocrine Biosciences | Healthcare | 3.80% | $379.65 | 694K | $113.0M |
| 7 | ARGXargenx SE () | Healthcare | 3.79% | $378.82 | 120K | $112.7M |
| 8 | EXELExelixis | Healthcare | 3.79% | $378.81 | 1.7M | $112.7M |
| 9 | ONCBeOne Medicines () | Healthcare | 3.78% | $378.07 | 279K | $112.5M |
| 10 | BMRNBioMarin Pharmaceutical | Healthcare | 3.72% | $372.26 | 1.8M | $110.8M |
| 11 | GILDGilead Sciences | Healthcare | 3.71% | $371.17 | 654K | $110.4M |
| 12 | BIIBBiogen | Healthcare | 3.70% | $369.86 | 438K | $110.1M |
| 13 | BRKRBruker | Healthcare | 3.57% | $356.99 | 1.7M | $106.2M |
| 14 | AMGNAmgen | Healthcare | 3.55% | $355.27 | 238K | $105.7M |
| 15 | VRTXVertex Pharmaceuticals Incorporated | Healthcare | 3.49% | $349.22 | 194K | $103.9M |
of the $345B in 58 Technology ETFs
| # | Ticker | Company | Weight ▼ |
|---|---|---|---|
| 1 | GMAB | Genmab A/S () | 4.57% |
| 2 | ADMA | ADMA Biologics | 4.35% |
| 3 | REGN | Regeneron Pharmaceuticals | 4.21% |
| 4 | TGTX | TG Therapeutics | 3.97% |
| 5 | ALKS | Alkermes | 3.83% |
| 6 | NBIX | Neurocrine Biosciences | 3.80% |
| 7 | ARGX | argenx SE () | 3.79% |
| 8 | EXEL | Exelixis | 3.79% |
| 9 | ONC | BeOne Medicines () | 3.78% |
| 10 | BMRN | BioMarin Pharmaceutical | 3.72% |
Estimated yearly cost excludes trading costs and assumes constant assets.
| Ex-date | Paid | Per share |
|---|---|---|
| Dec 13, 2024 | Dec 31, 2024 | $1.17 |
| Dec 30, 2021 | Jan 10, 2022 | $2.21 |
| Sep 23, 2015 | Sep 30, 2015 | $0.0200 |
| Jun 24, 2015 | Jun 30, 2015 | $0.0650 |
| Mar 25, 2015 | Mar 31, 2015 | $0.0480 |
| Dec 23, 2014 | Dec 31, 2014 | $0.0524 |
| Jun 23, 2008 | Jun 30, 2008 | $0.27 |